Chen Jiewei, Huang Chuqiang, Chen Keming, Li Shuman, Zhang Xinke, Cheng Jun, Cai Muyan, Xiao Yongbo
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine.
Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou.
Onco Targets Ther. 2018 Jan 19;11:441-448. doi: 10.2147/OTT.S152953. eCollection 2018.
Limb-bud and heart (LBH) levels are correlated with adverse survival in several malignancies; however, their significance in hepatocellular carcinoma (HCC) remains unclear. The objective of this study was to determine the association between LBH status and clinical outcomes.
We selected 226 patients with HCC who were treated surgically between 2003 and 2010 at a single academic center. Immunohistochemistry (IHC) was used to detect the protein expression of LBH in HCC samples. Receiver operating characteristic (ROC) curve analysis, Spearman's rank correlation, Kaplan-Meier plots, and the Cox proportional hazards regression model were used to analyze the data.
A high expression of LBH was detected in 20 (8.8%) of 226 HCC samples. Correlation analysis demonstrated that LBH in HCC was significantly correlated with aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels and clinical stages (<0.05). In the Kaplan-Meier analysis, the mean survival time of patients with low levels of LBH was longer than that for those with high levels of LBH (<0.05). The 3-year overall survival rate was 20% for patients with HCC and high levels of LBH versus 67% for patients with HCC and low levels of LBH. In the multivariate analysis, AST/ALT level, clinical stage, tumor relapse, and the level of LBH were the independent prognostic factors for overall survival (<0.05).
Overexpression of LBH might contribute to the development and progression of HCC. LBH could be a novel prognostic marker for HCC.
肢芽和心脏（LBH）水平与多种恶性肿瘤的不良生存相关；然而，其在肝细胞癌（HCC）中的意义仍不明确。本研究的目的是确定LBH状态与临床结局之间的关联。
我们选取了2003年至2010年间在单一学术中心接受手术治疗的226例HCC患者。采用免疫组织化学（IHC）检测HCC样本中LBH的蛋白表达。使用受试者工作特征（ROC）曲线分析、Spearman等级相关性分析、Kaplan-Meier曲线以及Cox比例风险回归模型对数据进行分析。
在226例HCC样本中，有20例（8.8%）检测到LBH高表达。相关性分析表明，HCC中的LBH与天冬氨酸转氨酶（AST）/丙氨酸转氨酶（ALT）水平及临床分期显著相关（<0.05）。在Kaplan-Meier分析中，LBH水平低的患者的平均生存时间长于LBH水平高的患者（<0.05）。HCC且LBH水平高的患者3年总生存率为20%，而HCC且LBH水平低的患者为67%。在多因素分析中，AST/ALT水平、临床分期、肿瘤复发和LBH水平是总生存的独立预后因素（<0.05）。
LBH的过表达可能促进HCC的发生和发展。LBH可能是HCC的一种新型预后标志物。
